Please Wait

Applying Filters...

Drug Product Composition: Sumatriptan Succinate

Sumatriptan Succinate

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

51 API Suppliers, 26 USDMF, 15 CEP/COS, 4 JDMF, 13 EU WC, 6 KDMF, 20 NDC API, 26 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

INTERMEDIATES

5 Intermediates Suppliers

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

386 FDF Dossiers, 97 FDA Orange Book, 212 Europe, 28 Canada, 15 Australia, 19 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 25MG BASE, TABLET;ORAL - EQ 50MG BASE, SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR, POWDER;NASAL - EQ 11MG BASE, SPRAY;NASAL - 20MG/SPRAY, SPRAY;NASAL - 5MG/SPRAY, TABLET;ORAL - 500MG;EQ 85MG BASE, TABLET;ORAL - 60MG;EQ 10MG BASE, INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

1 Parenteral, 1 Topical

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 34 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 178 Finished Drug Prices, 8 Annual Reports

MARKET PLACE

11 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

51 US Patents, 10 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 5 Others

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 21926 / DOSAGE - TABLET;ORAL - 60MG;EQ 10MG BASE

Ingredient Name	Basis of Strength	Strength
Active Ingredient/Active Moiety
NAPROXEN SODIUM(UNII: 9TN87S3A3C) (NAPROXEN - UNII:57Y76R9ATQ)	NAPROXEN SODIUM	500mg
SUMATRIPTAN SUCCINATE(UNII: J8BDZ68989) (SUMATRIPTAN - UNII:8R78F6L9VO)	SUMATRIPTAN	85mg

Inactive Ingredients

Ingredient Name	Glaxo Operations UK Ltd	Pernix Therapeutics	GlaxoSmithKline LLC
ANHYDROUS DIBASIC CALCIUM PHOSPHATE(L11K75P92J)
CALCIUM PHOSPHATE, DIBASIC, ANHYDROUS(L11K75P92J)
CARBOXYMETHYLCELLULOSE SODIUM(K679OBS311)
CARBOXYMETHYLCELLULOSE SODIUM, UNSPECIFIED FORM(K679OBS311)
CELLULOSE, MICROCRYSTALLINE(OP1R32D61U)
Croscarmellose Sodium(M28OL1HH48)
DEXTROSE MONOHYDRATE(LX22YL083G)
FD&C BLUE NO. 2(L06K8R7DQK)
HYPROMELLOSE, UNSPECIFIED(3NXW29V3WO)
LECITHIN, SOYBEAN(1DI56QDM62)
MAGNESIUM STEARATE(70097M6I30)
MALTODEXTRIN(7CVR7L4A2D)
MICROCRYSTALLINE CELLULOSE(OP1R32D61U)
Polyethylene Glycol, Unspecified(3WJQ0SDW1A)
POLYVINYL ALCOHOL, UNSPECIFIED(532B59J990)
POVIDONE, UNSPECIFIED(FZ989GH94E)
POVIDONES(FZ989GH94E)
SODIUM BICARBONATE(8MDF5V39QO)
Talc(7SEV7J4R1U)
TITANIUM DIOXIDE(15FIX9V2JP)
Triacetin(XHX3C3X673)

Drug Product Composition: Sumatriptan Succinate

Sumatriptan Succinate

Sumatriptan Succinate

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

51 API Suppliers

26 USDMF

15 CEP/COS

4 JDMF

13 EU WC

6 KDMF

20 NDC API

26 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

INTERMEDIATES

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

386 FDF Dossiers

97 FDA Orange Book

212 Europe

28 Canada

15 Australia

19 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 100MG BASE

TABLET;ORAL - EQ 25MG BASE

TABLET;ORAL - EQ 50MG BASE

SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR

POWDER;NASAL - EQ 11MG BASE

SPRAY;NASAL - 20MG/SPRAY

SPRAY;NASAL - 5MG/SPRAY

TABLET;ORAL - 500MG;EQ 85MG BASE

TABLET;ORAL - 60MG;EQ 10MG BASE

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

1 Parenteral

1 Topical

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow

34 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

178 Finished Drug Prices

8 Annual Reports

MARKET PLACE

11 APIs

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

51 US Patents

10 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM

3 USP

5 Others

Filters

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons